Please assess the completion status of the following clinical trial:

Trial Title: Ginsenoside-Rd for Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* between 18 to 75 years~* the first episode~* from onset to admission within 72 hours~* NIHSS scores:5\~22~Exclusion Criteria:~* had other intracranial pathologies (e.g., tumor, infection)~* had a neurologic or psychiatric disease~* had a coexisting condition that limited their life expectancy~* had significant drug or alcohol misuse~* had high-grade carotid artery stenosis for which surgery was planned~* were pregnant or nursing~* participated in a clinical trial with an investigational drug or device within the past 3 months~* were unlikely to be available for follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ginsenoside-Rd 10mg (Type: EXPERIMENTAL): both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.
- placebo (Type: PLACEBO_COMPARATOR): 2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.
- ginsenoside-Rd 20mg (Type: EXPERIMENTAL): 2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed

Based on this trial design, predict the completion outcome and termination type (if applicable).